Yahoo
HKSE - Delayed Quote HKD

LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. (2291.HK)

14.000 +0.380 (+2.79%)
At close: 4:08:07 PM GMT+8
Chart Range Bar
Loading chart for 2291.HK
  • Previous Close 13.620
  • Open 14.000
  • Bid 13.860 x --
  • Ask 13.990 x --
  • Day's Range 13.750 - 14.000
  • 52 Week Range 8.330 - 19.650
  • Volume 225,000
  • Avg. Volume 690,584
  • Market Cap (intraday) 4.76B
  • Beta (5Y Monthly) -0.17
  • PE Ratio (TTM) 21.21
  • EPS (TTM) 0.660
  • Earnings Date --
  • Forward Dividend & Yield 0.57 (4.20%)
  • Ex-Dividend Date May 27, 2026
  • 1y Target Est 29.79

LEPU ScienTech Medical Technology (Shanghai) Co., Ltd., an investment holding company, engages in the manufacture and sale of interventional treatment series occluders and heart valve medical devices. It operates through Occluder Business and Heart Valve Business segments. The company also researches, develops, manufacture, and sale interventional treatment series occluders for defective congenital heart disease; and manufacture and sale heart valve medical devices. Its products include atrial septal defect, ventricular septal defect, patent ductus arteriosus, patent foramen ovale, left atrial appendage, and aortic and peripheral occluders, as well as aortic and mitral valve occluder products; atrial septal puncture and procedural accessories; interatrial shunt device; mechanical circulatory support products; and hypertensive device treatment products. In addition, it is involved in manufacturing industry; technology development; and trading activities. The company serves its products through distributors and direct sales. LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. was incorporated in 1994 and is headquartered in Shanghai, the People's Republic of China. LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. operates as a subsidiary of Lepu Medical Technology (Beijing) Co., Ltd.

www.scientechmed.com

371

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/3/2026, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .

YTD Return

2291.HK
7.62%
HANG SENG INDEX (^HSI)
8.21%

1-Year Return

2291.HK
24.35%
HANG SENG INDEX (^HSI)
10.06%

3-Year Return

2291.HK
45.59%
HANG SENG INDEX (^HSI)
33.19%

5-Year Return

2291.HK
53.02%
HANG SENG INDEX (^HSI)
5.99%

Analyst Insights

View More

Analyst Price Targets

28.40
29.79 Average
14.000 Current
31.18 High

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    40.18%

  • Return on Assets (ttm)

    6.37%

  • Return on Equity (ttm)

    10.27%

  • Revenue (ttm)

    508.38M

  • Net Income Avi to Common (ttm)

    204.24M

  • Diluted EPS (ttm)

    0.660

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.29B

  • Total Debt/Equity (mrq)

    0.03%

  • Levered Free Cash Flow (ttm)

    37.17M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: